Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018
|出版日期||內容資訊||英文 90 Pages
|中國的體外診斷劑產業的調查與預測 Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018|
|出版日期: 2014年02月20日||內容資訊: 英文 90 Pages||
Research and Forecast of China IVD Reagent (In Vitro Diagnostic Reagent) Industry, 2014-2018 mainly conducts in-depth analysis on the external environment, market operation, import & export of China's IVD reagent industry, and also summaries the latest development of key Chinese domestic enterprises in 2013, and finally forecasts the future industrial development. The information can offer investors the decisive reference for their investment in the field.
IVD reagent industry is an emerging industry in China, the start is late and the development is relatively backward compares with occidental countries. According to the data provided by IVD Special Committee, there are 300 to 400 IVD reagent manufacturing enterprises in China, of which, 200 enterprises own above designated scale. However, only about 20 enterprises have the ability to achieve annual sales income of more than CNY 100 million; most of enterprises are in small scale and the product variety is few.
In 2013, the market scale of China's IVD industry reached CNY 22.5 billion; among them, the market scale of IVD reagents was about CNY 16.3 billion.
The state policy encourages the competitive enterprises to strengthen their strength. In 2013, a series of policies which target to improve industry standard and threshold entered the substantive operation stage, which accelerates the elimination of small enterprises and improves the industry concentration ratio. Industrial consolidation is the development trend, and the enterprises with capital, technology and scale advantages will win gradually.
In recent years, due to the continued sluggishness of European and American pharmaceutical market, the international giants target on the market expansion brought by China's new medical reform, and entered China's market in succession; after the China-oriented R&D center transfer, these powerful enterprises began to compete with China's enterprises in the low and medium-end markets through mergers, acquisitions, capital increase and production expansion; therefore, the competitive enterprises in China's diagnostic reagent subdivided industries will face more sever competitions.